Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 17/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660039 | 1.00 | GRIA4 (0.72) | GRIA4GRIA1GRIA2GRIA3MEN1 | |
| SCHEMBL3074752 | 1.00 | GRIA4 (0.72) | GRIA4GRIA1GRIA2GRIA3MEN1 | |
| SCHEMBL6563307 | 0.96 | GRIA4 (0.65) | GRIA4MEN1ALDH1A1LMNAHTT | |
| SCHEMBL6563308 | 0.90 | GRIA4 (0.56) | GRIA4MEN1ALDH1A1LMNAHTT | |
| SCHEMBL6565219 | 0.89 | GRIA4 (0.56) | GRIA4MEN1ALDH1A1LMNAHTT | |
| SCHEMBL5878035 | 0.87 | GRIA4 (0.74) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5992695 | 0.85 | GRIA4 (0.71) | GRIA4GRIA1GRIA2GRIA3 | |
| Mibampator SCHEMBL3045499 | 0.84 | GRIA4 (1.00) | GRIA4GRIA1GRIA2GRIA3POLB | |
| Mibampator SCHEMBL6660037 | 0.84 | GRIA4 (1.00) | GRIA4GRIA1GRIA2GRIA3POLB | |
| Mibampator SCHEMBL3074747 | 0.84 | GRIA4 (1.00) | GRIA4GRIA1GRIA2GRIA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005013961-A1 | COMBINATION THERAPY FOR TREATMENT OF COGNITIVE DISORDERS OR PSYCHOSES | ELI LILLY AND COMPANY (US) | 2005-02-17 | — | — | WO | claimed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | claimed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | claimed |
| US-20030225163-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1311474-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-05-21 | — | — | EP | claimed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | claimed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822498-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090055-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225163-A1 | Sulfonamide derivatives | GRIN1, SLC1A2, GRIN2A | GRIA4 17/4885GRIA1 8/4885GRIA2 10/4885 |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | COMT, DRD2, DRD3 | GRIA4 2544/4885GRIA1 2536/4885GRIA2 2040/4885 |
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | GRIA4 18/4885GRIA1 23/4885GRIA2 19/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | GRIA4 212/4885GRIA1 324/4885GRIA2 176/4885 |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, HTR1A | GRIA4 361/4885GRIA1 344/4885GRIA2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.